SecurityVFC / V.F. Corp.
Institution1832 Asset Management L.P.
Shares2,000
Value $ 148,000
Related QEPC / Q.E.P. Co., Inc.
USCS / USCorp.
918204AV0 / Vf Corp 3.50% Senior Notes 09/01/21
918204AS7 / Vf Corp. 5.95% Notes 11/1/17
918204AT5 / Vf Corp. 6.45% Notes 11/1/37
91820410R / V.F. Corp. COMMON STOCK
918204AR9 / Vf Corporation 6.000% Notes 10/15/33

1832 Asset Management L.P. ownership in VFC / V.F. Corp.

February 14, 2018 - 1832 Asset Management L.P. has filed a 13F-HR form disclosing ownership of 2,000 shares of V.F. Corp. (NYSE:VFC) with total holdings valued at $148,000 USD as of December 31, 2017. 1832 Asset Management L.P. had filed a previous 13F-HR on November 14, 2017 disclosing 0 shares of V.F. Corp. at a value of $0 USD.

Other investors with positions similar to 1832 Asset Management L.P. include City Holding Co, Carroll Financial Associates, Inc., Valeo Financial Advisors, Llc, Orrstown Financial Services Inc, Toth Financial Advisory Corp, and Edge Advisors, Llc.

V.F. Corp. has declared a standard industrial code (sic) of 232 which is the "Men's And Boys' Furnishings, Work Clothing, And Allied Garments" industry. 1832 Asset Management L.P.'s top industries are "Construction Special Trade Contractors" (sic 17), "Primary Metal Industries" (sic 33), and "Home Furniture, Furnishings, And Equipment Stores" (sic 57).

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-12-31 13F-HR V F COM 918204108 2,000 148
2017-09-30 13F-HR V F COM 918204108 0 -100.00 0 -100.00
2017-06-30 13F-HR V F COM 918204108 56.37 3,000 -99.63 173 -99.61 -45,127 1,046 2.36
2017-03-31 13F-HR V F COM 918204108 59.61 803,538 300.35 44,254 243.72 35,935 -4,556 -35.38
2016-12-31 13F-HR/A-1 V F COM 918204108 60.10 200,711 22.24 12,875 39.90 2,195 1,477 16.05
2016-12-31 13F-HR V F COM 918204108 163,358 8,941
2016-09-30 13F-HR V F COM 918204108 58.86 164,188 3,542.15 9,203 3,210.43 9,399 -474 -170.41
2016-06-30 13F-HR/A-1 V F COM 918204108 63.16 4,508 -62.63 278 -64.36 -477 -25 -3.18
2016-06-30 13F-HR V F COM 918204108 4,508 278
2016-03-31 13F-HR V F COM 918204108 63.52 12,063 -81.39 780 -80.71 -3,350 87 2.16
2015-12-31 13F-HR V F COM 918204108 65.41 64,803 -38.33 4,043 -43.77 -2,634 -513 -7.13
2015-09-30 13F-HR V F COM 918204108 67.88 105,074 -19.83 7,190 -18.53 -1,764 129 1.46
2015-06-30 13F-HR V F COM 918204108 71.32 131,062 24.23 8,825 11.08 1,823 -943 -11.87
2015-03-31 13F-HR V F COM 918204108 74.84 105,502 -77.48 7,945 -77.20 -27,174 266 0.76
2014-12-31 13F-HR V F COM 918204108 69.95 468,575 50.03 34,853 70.31 10,930 3,459 16.90
2014-09-30 13F-HR V F COM 918204108 64.08 312,321 0.99 20,464 5.64 196 896 4.62
2014-06-30 13F-HR V F COM 918204108 309,260 19,372

Related SEC Filings

VFC / V.F. Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
vfcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 2 )*       Name of issuer:  VF Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  918204108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)   (  ) Rul

VFC / V.F. Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
vfcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 2 )*       Name of issuer:  VF Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  918204108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)   (  ) Rul

VFC / V.F. Corp. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* V F CORP (Name of Issuer) Common Stock (Title of Class of Securities) 918204108 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cov

VFC / V.F. Corp. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* V F CORP (Name of Issuer) Common Stock (Title of Class of Securities) 918204108 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cov

VFC / V.F. Corp. / BlackRock Inc. - 3G (Passive Investment)

2018-02-08 sec.gov
us9182041080_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) V. F. CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 918204108 -------------------------------------------------------- (CUSIP Number) December 31, 2017 -----------------------------------------------------

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...



CUSIP: 918204108